Maestro Multi-Well Microelectrode Array System

The Food and Drug Administration published a Special Notice on February 27, 2023 to inform the public of its intent to issue a sole source contract award. The award is to procure one Axion Biosystem Maestro Multi-Well Microelectrode Array system for use by the FDA's Office of Acquisition and Grant Services.

The purpose of the notice is to acquire a system that meets the technical requirements detailed in the attached notice of intent. These requirements include integrated signal amplification, digitization and stimulation hardware, environmental chamber controls for temperature, CO2, humidity and gas mixtures, automated plate docking, barcode tracking, customizable electrical stimulation and stimulus design, and the ability to record from multiple well plate formats with multiple electrodes per well. Interested parties have until March 9, 2023 to submit capability statements for consideration, however, the FDA anticipates issuing the sole source award to Axion BioSystems as the only company deemed able to meet the specialized technical needs of the agency. The award will be issued in accordance with FAR 6.302-1 for procurements where there is only one responsible source and no other supplies or services will satisfy agency requirements.